What's Happening?
ImmunityBio, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ANKTIVA® in combination with Bacillus Calmette-Guerin (BCG) for treating patients with BCG-unresponsive
non-muscle invasive bladder cancer (NMIBC) with papillary disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 6, 2027. This acceptance follows the submission of additional scientific data by ImmunityBio, which supports the expansion of ANKTIVA's label to include patients with papillary tumors. The FDA's decision was influenced by discussions at a recent workshop where experts highlighted the biological similarities between carcinoma in situ (CIS) and papillary disease, suggesting that treatment approaches could be extrapolated from CIS to papillary disease.
Why It's Important?
The FDA's acceptance of the sBLA is a significant step towards expanding treatment options for patients with BCG-unresponsive NMIBC, a condition affecting approximately 85% of the 64,000 people diagnosed with NMIBC annually in the U.S. If approved, this expansion could provide a bladder-sparing treatment alternative, reducing the need for radical cystectomy, which is associated with high morbidity and mortality. The decision could also enhance ImmunityBio's market position by broadening the use of ANKTIVA, potentially increasing its commercial impact and providing a new therapeutic option for a larger patient population.
What's Next?
The FDA will review the scientific data provided by ImmunityBio to determine if the expansion of ANKTIVA's indication is justified. The outcome of this review will be crucial for ImmunityBio, as approval would allow the company to market ANKTIVA for a broader range of bladder cancer patients. Stakeholders, including healthcare providers and patients, will be closely monitoring the FDA's decision, which could influence treatment protocols and insurance coverage for NMIBC.
